Compare Becton Dickinson and Co (BDX) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares MSCI United Kingdom (FTSE) — how do they compare? Becton Dickinson and Co trades at $156.33 (market cap $41.51B), while iShares MSCI United Kingdom (FTSE) trades at $46.71. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | EWU | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $48.68 |
52-Week Low | $135.49 | $39.59 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
EWU, the iShares MSCI United Kingdom ETF, trades at $46.36, down 0.52% on the day, with technical indicators showing a neutral to bearish bias. The ETF's performance is heavily influenced by UK economic conditions and political developments, including recent leadership changes. Key holdings in financials, consumer staples, and healthcare drive its NAV, with the top 10 holdings comprising over half of the portfolio.
Outlook remains cautious due to UK political instability and economic headwinds, though potential exists from M&A activity and valuation discounts. Risks include sterling volatility and fiscal constraints. Analyst sentiment is mixed, reflecting uncertainty over near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
